The quick answer
Mounjaro (tirzepatide) produced more average weight loss than Wegovy (semaglutide) in a direct trial (~20.2% vs 13.7%). Wegovy is usually cheaper and has been registered for weight management slightly longer in SA. Both are once-weekly. If maximum results matter most, Mounjaro leads; if price or availability matters more, Wegovy is compelling.
Wegovy vs Mounjaro: side by side
| Feature | Wegovy | Mounjaro |
|---|---|---|
| Active ingredient | Semaglutide (GLP-1) | Tirzepatide (GIP + GLP-1) |
| SA registration | Chronic weight management | Diabetes + weight management (late 2025) |
| Avg. weight loss | ~13.7% (SURMOUNT-5) | ~20.2% (SURMOUNT-5) |
| Typical price / month | R1 900 – R3 750 | R3 500 – R4 600 |
| How often | Once weekly | Once weekly |
| Form | Multi-dose pen | Single-dose pens / vials |
Which might suit you
Lean Mounjaro for the largest average weight loss. Lean Wegovy for lower cost, a familiar pen, and an on-label weight-management option that's widely stocked. Some people start on Wegovy and consider Mounjaro later, or vice versa — a provider can advise on the right sequence.
This is general information, not a recommendation for your situation. The right choice depends on your health, budget, what's in stock and a clinician's judgement. Get a personalised assessment from a registered provider
Next step